New anti-tuberculosis drugs: Strategies, sources and new molecules

Current Medicinal Chemistry

Volumn 16, Issue 15, 2009, Pages 1898-1904

  Palomino, Juan Carlos ^a   Ramos, Daniela Fernandes ^b   da Silva, Pedro Almeida ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

Chemical compounds; Drugs; Natural products; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 1 ISONICOTINYL 2 NONANOYLHYDRAZINE; 1,5 BIS(4 CHLOROPHENYL) 2 METHYL 3 (4 METHYL 1 PIPERAZINYLMETHYL)PYRROLE; 2 ETHYL 5 NITRO 2,3 DIHYDRO[2 1B]IMIDAZOOXAZOLE; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; [5 HYDROXY 5 (TRIFLUOROMETHYL) 4,5 DIHYDRO 1H PYRAZOL 1YL](PYRIDIN 4 YL)METHANONE; ANTIMALARIAL AGENT; CGI 17341; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; ISONIAZID DERIVATIVE; LEVOFLOXACIN; LL 3858; METRONIDAZOLE; MOXIFLOXACIN; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NAS 21; NAS 91; NATURAL PRODUCT; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; PEPTIDE DEFORMYLASE INHIBITOR; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; CLINICAL TRIAL; COLONY FORMING UNIT M; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HEMOLYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; LIVER TOXICITY; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; TUBERCULOSIS;

EID: 68449086364     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788186066     Document Type: Review

References (66)

1. World Health Organization. Global tuberculosis control: Surveillance, planning, financing: WHO report 2008. WHO/HTM/TB/2008.393
2. Humer, F. Innovation in the Pharmaceutical Industry-Future Prospects. 2008. Available at: http://www.roche.com/fbh_zvg05_e.pdf Accessed on 17 November 2008.
3. Goulding, C.W.; Apostol, M.; Anderson, D.H.; Gill, H.S.; Smith, C.V.; Kuo, M.R.; Yang, J.K.; Waldo, G.S.; Suh, S.W.; Chauhan, R.; Kale, A.; Bachhawat, N.; Mande, S.C.; Johnston, J.M.; Lott, J.S.; Baker, E.N.; Arcus, V.L.; Leys, D.; McLean, K.J.; Munro, A.W.; Berendzen, J.; Sharma, V.; Park, M.S.; Eisenberg, D.; Sacchettini, J.; Alber, T.; Rupp, B.; Jacobs, W. Jr.; Terwilliger, and T.C. The TB structural genomics consortium: Providing a structural foundation for drug discovery. Cur. Drug Targets Infect. Disord., 2002, 2, 121-141
4. Boshoff, H.I.; Myers, T.G.; Copp, B.R.; McNeil, M.R.; Wilson, M.A.; Barry, C.E. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action. J. Biol. Chem., 2000, 279, 40174-40184.
5. Hasan, S.; Daugelat, S.; Rao, P.S.; Schreiber, M. Prioritizing genomic drug targets in pathogens: Application to Mycobacterium tuberculosis. PLoS Comput. Biol., 2006, 2, e61.
6. Murphy, D.J.; Brown, J.R. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect. Dis., 2007, 7, 84.
7. Young, D.; Stark, J.; Kirschner. D. Systems biology of persistent infection: Tuberculosis as a case study. Nat. Rev. Microbiol., 2008, 6, 520-528.
8. Boshoff, H.I.; Manjunatha.J.H. The impact of genomics on discovering drugs against infectious diseases. Microbes Infect. 2006, 8, 1654-1661.
9. Mdluli, K.; Spigelman, M. Novel targets for tuberculosis drug discovery. Curr. Opin. Pharmacol., 2006, 6, 459-467.
10. Kana, B.D.; Mizrahi, V. Molecular genetics of Mycobacterium tuberculosis in relation to the discovery of novel drugs and vaccines. Tuberculosis (Edinb.), 2004, 84, 63-75.
11. Arcuri, H.A.; Borges, J.C.; Fonseca, I.O.; Pereira, J.H.; Neto, J.R.; Basso, L.A.;. Santos, D.S.; de Azevedo, W.F. Jr. Structural studies of shikimate 5-dehydrogenase from Mycobacterium tuberculosis. Proteins, 2008, 72, 720-730.
12. Sacchettini, J.C.; Rubin, E.J.; Freundlich, J.S. Drugs versus bugs: In pursuit of the persistent predator Mycobacterium tuberculosis. Nat. Rev. Microbiol., 2008, 6, 41-52.
13. Chung, G.A.; Aktar, Z.; Jackson, S.; Duncan, K. High-throughput screen for detecting antimycobacterial agents. Antimicrob. Agents Chemother., 1995, 39, 2235-2238.
14. Stavri, M.; Mathew, K.T.; Bucar, F.; Gibbons, S. Pangelin, an antimycobacterial coumarin from Ducrosia anethifolia. Planta Med., 2003, 69, 956-959.
15. Barker, L.P.; Lien, B.A.; Brun, O.S.; Schaak, D.D.; McDonough, K.A.; Chang, L.C. A Mycobacterium marinum zone of inhibition assay as a method for screening potential antimycobacterial compounds from marine extracts. Planta Med., 2007, 73, 559-563.
16. Palomino, J.C.; Martin, A.; Camacho, M.; Guerra, H.; Swings, J.; Portaels, F. Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2002, 46, 2720-2722.
17. Martin, A.; Camacho, M.; Portaels, F.; Palomino, J.C. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: Rapid, simple, and inexpensive method. Antimicrob. Agents Chemother., 2003, 47, 3616-3619.
18. Lemus, D.; Montoro, E.; Echemendia, M.; Martin, A.; Portaels, F.; Palomino, J.C. Nitrate reductase assay for detection of drug resistance in Mycobacterium tuberculosis: Simple and inexpensive method for low-resource laboratories. J. Med. Microbiol., 2006, 55, 861-863.
19. Cho, S.H.; Warit, S.; Wan, B.; Hwang, C.H.; Pauli, G.F.; Franzblau, S.G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2007, 51, 1380-1385.
20. Taneja, N.K.; Tyagi, J.S. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J. Antimicrob. Chemother., 2007, 60, 288-293.
21. Cenciarini-Borde C., Courtois S., La Scola B. Nucleic acids as viability markers for bacteria detection using molecular tools. Future Microbiol., 2009, 4, 45-64.
22. Singh, S.B.; Barrett, J.F. Empirical antibacterial drug discovery--foundation in natural products. Biochem. Pharmacol., 2006, 71, 1006-1015.
23. Pelaez, F. The historical delivery of antibiotics from microbial natural products--can history repeat? Biochem. Pharmacol., 2006, 71, 981-990.
24. Okunade, A.L.; Elvin-Lewis, M.P.; Lewis, W.H. Natural antimycobacterial metabolites: Current status. Phytochemistry, 2004, 65, 1017-1032.
25. Mata, R.; Morales, I.; Perez, O.; Rivero-Cruz, I.; Acevedo, L., Enriquez-Mendoza, I.; Bye, R.; Franzblau, S.G.; Timmermann, B. Antimycobacterial compounds from Piper sanctum. J. Nat. Prod., 2004, 67, 1961-1968.
26. Rojas, R.; Caviedes, L.; Aponte, J.C.; Vaisberg, A.J.; Lewis, W.H.; Lamas, G.; Sarasara, C.; Gilman, R.H.; Hammond. G.B. Aegicerin, the first oleanane triterpene with wide-ranging antimycobacterial activity, isolated from Clavija procera. J. Nat. Prod., 2006, 69, 845-846.
27. Azevedo, L.G.; Muccillo-Baisch, A.L.; Filgueira, D.M.; Boyle, R.T.; Ramos, D.F.; Soares, A.D.; Lerner, C.; Silva, P.A.; Trindade, G.S. Comparative cytotoxic and anti-tuberculosis activity of Aplysina caissara marine sponge crude extracts. Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 2008, 147, 36-42.
28. Pauli, G.F.; Case, R.J.; Inui, T.; Wang, Y.; Cho, S.; Fischer, N.H.; Franzblau, S.G. New perspectives on natural products in TB drug research. Life Sci., 2005, 78, 485-494.
29. Stermitz, F.R.; Lorenz, P.; Tawara, J.N.; Zenewicz, L.A.; Lewis, K. Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc. Natl. Acad. Sci. U.S.A, 2000, 97, 1433-1437
30. Lechner, D.; Gibbons, S.; Bucar, F. Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis. J. Antimicrob. Chemother., 2008, 62, 345-348.
31. Shaharyar, M.; Siddiqui, A.A.; Ali, M.A.; Sriram, D.; Yogeeswari, P. Synthesis and in vitro antimycobacterial activity of N1-nicotinoyl-3-(4'-hydroxy-3'-methyl phenyl)-5-(sub)phenyl-2-pyrazolines. Bioorg. Med. Chem. Lett., 2006, 16, 3947-3949.
32. Almeida da Silva, P.E.; Ramos, D.F.; Bonacorso, H.G.; de la Iglesia, A.I.; Oliveira, M.R.; Coelho, T.; Navarini, J.; Morbidoni, H.R.; Zanatta, N.; Martins, M.A. Synthesis and in vitro antimycobacterial activity of 3-substituted 5-hydroxy-5-trifluoro chloro methyl-4,5-dihydro-1H-1-(isonicotinoyl) pyrazoles. Int. J. Antimicrob. Agents, 2008, 32, 139-144.
33. Maccari, R.; Ottana, R.; Vigorita, M.G. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: Part 14. Bioorg. Med. Chem. Lett., 2005, 15, 2509-2513.
34. Nahid, P.; Pai, M.; Hopewell, P.C. Advances in the diagnosis and treatment of tuberculosis. Proc. Am. Thorac. Soc., 2006, 3, 103-110.
35. Hu, Y.; Coates, A.R.; Mitchison, D.A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2003, 47, 653-657.
36. Johnson, J. L.; Hadad, D.J.; Boom, W.H.; Daley, C.L.; Peloquin, C.A.; Eisenach, K.D.; Jankus, D.D.; Debanne, S.M.; Charlebois, E.D.; Maciel, E.; Palaci, M.; Dietze, R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis., 2006, 10, 605-612.
37. Nuermberger, E.L.; Yoshimatsu, T.; Tyagi, S.; O'Brien, R.J.; Vernon, A.N.; Chaisson, R.E.; Bishai, W.R.; Grosset, J.H. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med., 2004, 169, 421-426.
38. Ginsberg, A.M.; Spigelman, M. Challenges in tuberculosis drug research and development. Nat. Med., 2007, 13, 290-294.
39. Frothingham, R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin. Infect. Dis., 2005, 41, 1269-1276.
40. Biggs, W.S. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J. Am. Board Fam. Pract., 2003, 16, 455-457.
41. Park-Wyllie, L.Y.; Juurlink, D.N.; Kopp, A.; Shah, B.R.; Stukel, T.A.; Stumpo, C.; Dresser, L.; Low, D.E.; Mamdani, M.M. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med., 2006, 354, 1352-1361.
42. Teo, J.W.; Thayalan, P.; Beer, D.; Yap, A.S.; Nanjundappa, M.; Ngew, X.; Duraiswamy, J.; Liung, S.; Dartois, V.; Schreiber, M.; Hasan, S.; Cynamon, M.; Ryder, N.S.; Yang, X.; Weidmann, B.; Bracken, K.; Dick, T.; Mukherjee. K. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother., 2006, 50, 3665-3673.
43. Cynamon, M.H.; Alvirez-Freites, E.; Yeo, A.E. BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J. Antimicrob. Chemother., 2004, 53, 403-405.
44. Ashtekar, D.R.; Costa-Perira, R.; Nagrajan, K.; Vishvanathan, N.; Bhatt, A.D.; Rittel, W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Agents Chemother., 1993, 37, 183-186.
45. Stover, C.K.; Warrener, P.; Van Devanter, D.R.; Sherman, D.R.; Arain, T.M.; Langhorne, M.H.; Anderson, S.W.; Towell, J.A.; Yuan, Y.; McMurray, D.N.; Kreiswirth, B.N.; Barry, C.E.; Baker, W.R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.
46. Rivers, E.C.; Mancera, R.L. New anti-tuberculosis drugs with novel mechanisms of action. Curr. Med. Chem., 2008, 15, 1956-1967.
47. Onyebujoh, P.; Zumla, A.; Ribeiro, I.; Rustomjee, R.; Mwaba, P.; Gomes, M.; Grange, J.M. Treatment of tuberculosis: Present status and future prospects. Bull. World Health Organ, 2005, 83, 857- 865.
48. Manjunatha, U.H.; Boshoff, H.; Dowd, C.S.; Zhang, L.; Albert, T.J.; Norton, J.E.; Daniels, L.; Dick, T.; Pang, S.S.; Barry, III. C.E. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A, 2006, 103, 431-436.
49. Nuermberger, E.; Rosenthal, I.; Tyagi, S.; Williams, K.N.; Almeida, D.; Peloquin, C.A. Bishai, W.R.; Grosset, J.H. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother., 2006, 50, 2621-2625.
50. Yendapally, R.; Lee, R.E. Design, synthesis, and evaluation of novel ethambutol analogues. Bioorg. Med. Chem. Lett., 2008, 18, 1607-1611.
51. Chen, P.; Gearhart, J.; Protopopova, M.; Einck, L.; Nacy, C.A. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother., 2006, 58, 332-337.
52. Barry, P.J.; O'Connor, T.M. Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chem., 2007, 14, 2000-2008.
53. Deidda, D.; Lampis, G.; Fioravanti, R.; Biava, M.; Porretta, G.C.; Zanetti, S.; Pompei, R. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother., 1968, 42, 3035-3037.
54. Biava, M.; Porretta, G.C.; Poce, G.; Supino, S.; Deidda, D.; Pompei, R.; Molicotti, P; Manetti, F.; Botta, M. Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. J. Med. Chem., 2006, 49, 4946-4952.
55. Arora, S.K.; Sinha, N.; Sinha, R.; Bateja, R.; Sharma, S.; Upadhayaya, R.S. Design, synthesis, modelling and activity of novel anti tubercular compounds. Abstract n.63 submitted to the American Chemical Society Meeting, Anheim CA, March 28-April 01 2004 http://wiz2.pharm.wayne.edu/mediabstracts2004.pdf
56. Gratraud, P.; Surolia, N.; Besra, G.S.; Surolia, A.; Kremer, L. Antimycobacterial activity and mechanism of action of NAS-91. Antimicrob. Agents Chemother., 2008, 52, 1162-1166
57. Bhowruth, V.; Brown, A.K.; Besra, G.S. Synthesis and biological evaluation of NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FAS-II dehydratase enzyme Rv0636. Microbiology, 2008, 154, 1866-1875.
58. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H.W.; Neefs, J.M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227.
59. Cole, S.T.; Alzari, P.M. Microbiology. TB--a new target, a new drug. Science, 2005, 307, 214-215.
60. Lounis, N.; Veziris, N.; Chauffour, A.; Truffot-Pernot, C.; Andries, K.; Jarlier, V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother., 2006, 50, 3543-3547.
61. Jia, L.; Tomaszewski, J.E.; Hanrahan, C.; Coward, L.; Noker, P.; Gorman, G.; Nikonenko, B.; Protopopova, M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol., 2005, 144, 80-87.
62. Nikonenko, B.V.; Protopopova, M.; Samala, R.; Einck, L.; Nacy, C.A. Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother., 2007, 51, 1563- 5655.
63. Spigelman, M.K. New tuberculosis therapeutics: A growing pipeline. J. Infect. Dis., 2007, 196(Suppl. 1), S28-S34.
64. Rustomjee, R.; Lienhardt, C.; Kanyok, T.; Davies, G.R.; Levin, J.; Mthiyane, T.; Reddy, C.; Sturm, A.W.; Sirgel, F.A.; Allen, J.; Coleman, D.J.; Fourie, B.; Mitchison, D.A. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis., 2008, 12, 128-138.
65. Rustomjee, R.; Diacon, A.H.; Allen, J.; Venter, A.; Reddy, C.; Patientia, R.F.; Mthiyane, T.C.; De Marez, T.; van Heeswijk, R.; Kerstens, R.; Koul, A.; De Beule, K.; Donald, P.R.; McNeeley, D.F. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother., 2008, 52, 2831-2835.
66. http://www.tballiance.org/new/portfolio/html-portfolio-item.php? d=18. Accessed on 20 November 2008.